68

Gempharmatech Co. Ltd. A

688046 · SHG · Healthcare / Biotechnology

32.47CNY-2.03 (-5.88%)

Price History

Full chart

Market Stats

Previous Close34.50
Open34.05
Day Range32.00 – 34.19
52-Week Range12.75 – 43.47
Volume6.22M
Market Cap15.56B
P/E (TTM)84.31
Forward P/E0.00
EPS0.45
Dividend Yield0.58%
Beta0.90
50-Day Avg32.69
200-Day Avg22.07

About

GemPharmatech Co., Ltd., a contract research organization, provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. The company offers mouse models, including knockout and conditional knockout mouse, knock-in mouse, point-mutation mouse, transgenic mouse, immunodeficient mouse, germ-free mouse, and tool mice models, as well as operates wild mouse project. It also provides custom model generation, preclinical testing, germ-free and microbiome, cell lines and customization, custom breeding, animal quality testing, and other services. The company has a strategic alliance with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the discovery of new therapeutic antibodies. The company was founded in 2017 and is headquartered in Nanjing, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Xiang Gao Ph.D.
  • Employees1.69K
  • HeadquartersNo. 12 Xuefu Road, Nanjing, China, 210032, China
  • Websitehttps://www.gempharmatech.com

Leadership

  • Dr. Xiang Gao Ph.D.President & Chairman of the Board · b. 1963
  • Dr. Jing Zhao Ph.D.GM & Director · b. 1981
  • Mr. Yiou WangCFO & Board Secretary · b. 1984
  • Mr. Tao WangDeputy GM & Director · b. 1985
  • Yekun LiuAccounting Supervisor
  • Ms. Hongyan SunCore Technical Personnel · b. 1987
  • Mr. Juan LiangCore Technical Personnel · b. 1983

Financials

Income Statement

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue192.72M261.92M393.79M516.55M622.19M686.84M793.39M
Growth (%)-+35.91%+50.35%+31.17%+20.45%+10.39%+15.51%
Cost of Revenue63.90M73.24M101.09M147.82M201.52M261.05M284.43M
Gross Profit128.82M188.68M292.70M368.73M420.67M425.78M508.96M
Gross Margin66.84%72.04%74.33%71.38%67.61%61.99%64.15%
Operating Expense79.18M91.00M142.11M197.11M254.32M303.44M326.97M
Operating Income49.64M97.67M150.59M171.62M166.35M122.35M181.99M
Operating Margin25.76%37.29%38.24%33.22%26.74%17.81%22.94%
EBITDA54.54M108.91M172.87M213.25M217.78M208.36M259.21M
EBITDA Margin28.30%41.58%43.90%41.28%35.00%30.34%32.67%
Net Income34.74M76.43M124.93M164.67M158.91M109.82M142.64M
Net Income Margin18.03%29.18%31.72%31.88%25.54%15.99%17.98%
R&D30.31M48.22M55.20M82.93M96.60M87.13M92.06M
R&D as % of Total Revenue15.72%18.41%14.02%16.05%15.53%12.69%11.60%
Interest Expense255.14K723.98K744.85K495.53K2.76M4.30M6.08M
Interest Expense % of Total Revenue0.13%0.28%0.19%0.10%0.44%0.63%0.77%

Balance Sheet

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets388.14M883.19M1.05B2.25B2.58B2.57B2.87B
Total Liabilities147.66M225.95M268.78M276.00M452.93M437.92M637.87M
Total Equity240.47M657.24M785.63M1.98B2.12B2.13B2.23B
Cash221.90M524.17M293.52M421.71M560.17M701.37M486.62M

Cash Flow

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow65.12M129.79M113.31M105.98M116.57M90.31M227.03M
Capital Expenditure45.66M167.07M89.07M190.31M205.90M113.68M104.99M
Free Cash Flow19.47M-37.28M24.24M-84.33M-89.33M-23.36M122.04M
Dividends Paid235.81K672.32K679.96K283.50K17.87M80.11M61.22M
FCF to OCF29.89%-28.73%21.39%-79.57%-76.63%-25.87%53.75%
Dividend Paid to FCF1.21%-1.80%2.81%-0.34%-20.00%-342.91%50.17%

Earnings

Report DateAug 19, 2022Oct 30, 2022Apr 19, 2023
EPS Estimate---
EPS Actual0.130.110.09
Surprise---
TimingAfter-hoursAfter-hoursPre-market

Key Statistics & Ratios

Market Cap15.56B
Enterprise Value15.03B
Trailing P/E84.31
Forward P/E0.00
Price / Sales17.72
Price / Book6.99
EPS0.45
Book Value5.54
Revenue (TTM)878.13M
Gross Profit (TTM)558.09M
EBITDA264.12M
Profit Margin20.79%
Operating Margin25.51%
Return on Equity8.23%
Return on Assets4.16%
Shares Outstanding410.19M
Shares Float165.95M
Beta0.90
Dividend Yield0.58%
Dividend Rate0.22
Payout Ratio73.33%

Dividends

20262×
0.13Oct 22, 20260.19Jun 9, 2026
20252×
0.03Nov 20, 20250.11Jul 11, 2025
20242×
0.03Nov 4, 20240.16Aug 7, 2024
20231×
0.04Jul 7, 2023